Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer

International Journal of Clinical Oncology

Volumn 9, Issue 2, 2004, Pages 85-91

  Douwes, Friedrich ^a   Bogovič, Juri ^a   Douwes, Ortrun ^a   Migeod, Friedrich ^a   Grote, Christoph ^a  

^a Klinik St Georg   (Germany)

Author keywords

Carboplatin; Cisplatin; Ovarian cancer; Whole body hyperthermia

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; FENTANYL; FLUOROURACIL; GEMCITABINE; MIDAZOLAM; MORPHINE; NAVELBINE; PACLITAXEL; PROPOFOL; TOPOTECAN; TREOSULFAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BURN; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CORE TEMPERATURE; DRUG RESPONSE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC THERAPY; LEUKOPENIA; OVARY CANCER; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECTUM TEMPERATURE; SURVIVAL TIME; THROMBOCYTOPENIA; VALIDATION PROCESS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 2442597780     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0369-x     Document Type: Article

References (36)

1. Markman M, Rothman R, Hakes T, et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393
2. Bicher HI, Hetzel FW, Sandhu TS, et al. (1980) Effects of hyperthermia on normal and tumour microenvironment. Radiology 137:523-530
3. Schaefer C, Mayer WK, Kruger W, et al. (1993) Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia. J Cancer Res Clin Oncol 119:599-608
4. Vaupel P, Ostheimer K, Muller-Klieser W (1980) Circulatory and metabolic responses of malignant tumours during localized hyperthermia. J Cancer Res Clin Oncol 98:15-29
5. Vujaskovic Z, Poulson JM, Gaskin AA, et al. (2000) Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 46:179-185
6. Bogovic J, Douwes F, Muravjov G, et al. (2001) Posttreatment histology and microcirculation status of osteogenic sarcoma after a neoadjuvant chemo- and radiotherapy in combination with local electromagnetic hyperthermia. Onkologie 24:55-58
7. Li Q, Bostick-Bruton F, Reed E (1998) Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res 18:2283-2287
8. Osman A el-M, Ahmed MM, Khayyal MT, et al. (1993) Hyperthermic potentiation of cisplatin cytotoxicity on solid Ehrlich carcinoma. Tumori 31;79:268-272
9. Sakaguchi Y, Stephens LC, Makino M, et al. (1995) Apoptosis in tumours and normal tissues induced by whole body hyperthermia in rats. Cancer Res 55:5459-5464
10. Katschinski DM, Wiedemann GJ, Longo W, et al. (1999) Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev 10:93-97
11. Neville AJ, Sauder DN (1988) Whole body hyperthermia (41-42°C) induces interleukin-1 in vivo. Lymphokine Res 7:201-206
12. Multhoff G (1997) Heat shock protein 72 (HSP72), a hyperthermia-inducible immunogenic determinant on leukemic K562 and Ewing's sarcoma cells. Int J Hyperthermia 13:39-48
13. Roigas J, Wallen ES, Loening SA, et al. (1998) Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv Exp Med Biol 451:225-229
14. Hettinga JV, Lemstra W, Meijer C, et al. (1997) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 75:1735-1743
15. Wiedemann G, Roszinski S, Biersack A, et al. (1992) Local hyperthermia enhances cyclophosphamide, ifosfamide and cisdiamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. J Cancer Res Clin Oncol 118:129-135
16. Wiedemann GJ, Siemens HJ, Mentzel M, et al. (1993) Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide. Cancer Res 53:4268-4272
17. Wehner H, von Ardenne A, Kaltofen S (2001) Whole-body hyperthermia with water-filtered infrared radiation: technical-physical aspects and clinical experiences. Int J Hyperthermia 17:19-30
18. Steinhausen D, Mayer WK, von Ardenne M (1994) Evaluation of systemic tolerance of 42.0 degrees C infrared-A whole-body hyperthermia in combination with hyperglycemia and hyperoxemia. A phase-I study. Strahlenther Onkol 170:322-334
19. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345:540-543
20. Vernon CC, Hand JW, Field SB, et al. (1996) Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 35:731-744
21. Valdagni R, Amichetti M (1994) Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 28:163-169
22. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al. (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355:1119-1125
23. Robins HI, Cohen JD, Schmitt CL, et al. (1993) Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 11:1787-1794
24. Wiedemann GJ, d'Oleire F, Knop E, et al. (1994) Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 54:5346-5350
25. Aabo K, Adams M, Adnitt P, et al. (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78:1479-1487
26. Roland PY, Barnes MN, Niwas S, et al. (1998) Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Gynecol Oncol 68:178-182
27. Ghamande SA, Piver MS (1999) Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. J Surg Oncol 72:162-166
28. van der Burg ME, Hoff AM, van Lent M, et al. (1991) Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 27:248-250
29. Dobbs SP, Gribbin C, Chan SY, et al. (1994) Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. Eur J Cancer 30A:30-33
30. Averill DA, Su C (1999) Sensitization to the cytotoxicity of adriamycin by verapamil and heat in multidrug-resistant Chinese hamster ovary cells. Radiat Res 151:694-702
31. Raaphorst GP, Doja S, Davis L, et al. (1996) A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment. Cancer Chemother Pharmacol 37:574-580
32. Wallner KE, DeGregorio MW, Li GC (1986) Hyperthermic potentiation of cisplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 46:6242-6245
33. Westermann AM, Grosen EA, Katschinski DM, et al. (2001) A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 37:1111-1117
34. Wiedemann GJ, Robins HI, Gutsche S, et al. (1996) Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. Eur J Cancer 32A:888-892
35. Bull JM, Bigham CJ, Cronau LH, et al. (1992) A phase II study of whole body hyperthermia with mitomycin C (mito-C) and continuous iv (civ) 5-fluorouracil (5-FU) in colon cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 33:A1500
36. Bull JM, Cronau LH, Newman BM, et al. (1992) Chemotherapy resistant sarcoma treated with whole body hyperthermia combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Int J Hyperthermia 8:297-304